Accuray (ARAY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Young Li from Jefferies reiterated a Buy rating on the stock and has a $5.50 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Young Li’s rating is based on Accuray’s impressive financial performance and strategic positioning in key markets. The company reported a significant revenue beat, driven by robust growth in China and the broader Asia-Pacific region, as well as strong sales of its Cyberknife product. This performance was further supported by an improved gross margin and EBITDA margin, both of which exceeded consensus expectations.
Accuray’s ability to capture market share in China, alongside favorable trends in India and the uptake of its advanced technologies, reinforces its positive outlook. Additionally, the company has shown resilience against potential tariff impacts, maintaining a minimal risk profile in this regard. With an optimistic revenue and EBITDA forecast for the coming fiscal year, these factors collectively underpin the Buy rating from Young Li.
According to TipRanks, Li is an analyst with an average return of -17.0% and a 29.63% success rate. Li covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Cooper Co, and Accuray.
In another report released on February 6, BTIG also reiterated a Buy rating on the stock with a $6.00 price target.